Reference is made to the previous stock exchange announcements published by
Lifecare ASA (the "Company") regarding the completion of the Rights Issue.

Hannibal Invest AS, a company closely associated with Hans Hekland, board
member of the Company, has 27 June 2024 subscribed 65,599 shares at a price of
NOK 1,52442 per share, as compensation for the underwriting commitment made in
connection with the Rights Issue. Please see the attached PDMR-form for
further details.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication at
2024-07-02 17:25 CEST.